Brad Hariharan shares a concise post on the Big Pharma Biotech slump with a link to the original article.
Big Pharma Biotech M&A Slump in 2024 – is the answer early-stage private companies instead? Interesting insights from Bloomberg on the evolving trends in healthcare M&A.
Pharma giants are now eyeing smaller, private firms with promising early-stage drugs, signaling a strategic shift. This move highlights a period of strategic digestion and the rise of innovative biotechs in the private market. Although blockbuster deals are paused, the industry’s quest for innovation persists. Anticipate a surge in M&A activity as the current pipeline matures.
Link to Bloomberg article in comments.